References
- Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A. 2001; 98:3282–7.
- Baba T, Michikawa Y, Kashiwabara S, Arai Y. Proacrosin activation in the presence of a 32-kDa protein from boar spermatozoa. Biochem Biophys Res Commun. 1989; 160:1026–32.
- Baba T, Niida Y, Michikawa Y, Kashiwabara S, Kodaira K, Takenaka M, et al. An acrosomal protein, sp32, in mammalian sperm is a binding protein specific for two proacrosins and an acrosin intermediate. J Biol Chem. 1994; 269:10133–40.
- Wilkinson MF, Kleeman J, Richards J, MacLeod CL. A novel oncofetal gene is expressed in a stage-specific manner in murine embryonic development. Dev Biol. 1990; 141:451–5.
- Ono T, Sato S, Kimura N, Tanaka M, Shibuya A, Old LJ, Nakayama E. Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen. Int J Cancer. 2000; 88:845–51.
- Li X, Yan J, Fan R, Luo B, Zhang Q, Lin Y, et al. Serum immunore-activity of cancer/testis antigen OY TES-1 and its tissues expression in glioma. Oncol Lett. 2017; 13:3080–6.
- Fu X-D, Ares M, Jr. Context-dependent control of alternative splicing by RNA binding proteins. Nat Rev Genet. 2014; 15:689–701.
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409(6822):860–921.
- Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta. 2005; 1739:91–103.
- Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016; 16:413–30.
- Kanemori Y, Koga Y, Sudo M, Kang W, Kashiwabara S-I, Ikawa M, et al. Biogenesis of sperm acrosome is regulated by pre-mRNA alternative splicing of Acrbp in the mouse. Proc Natl Acad Sci U S A. 2016; 113:E3696–705.
- Black MW, Tuan A, Jonasson E. Cloning yeast actin cDNA leads to an investigative approach for the molecular biology laboratory. Biochem Mol Biol Educ. 2008; 36:217–24.
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016; 131:803–20.
- Pertea M, Shumate A, Pertea G, Varabyou A, Breitwieser FP, Chang Y-C. CHESS: a new human gene catalog curated from thousands of large-scale RNA sequencing experiments reveals extensive transcriptional noise. Genome Biol. 2018; 19:208. doi: 10.1186/s13059-018-1590-2
- Ast G. How did alternative splicing evolve? Nat Rev Genet. 2004; 5:773–82.
- Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012; 8:e1002772. doi: 10.1371/journal.pgen.1002772
- Baek D, Green P. Sequence conservation, relative isoform frequencies, and nonsense-mediated decay in evolutionarily conserved alternative splicing. Proc Natl Acad Sci U S A. 2005; 102:12813–8.
- Grasso C, Modrek B, Xing Y, Lee C. Genome-wide detection of alternative splicing in expressed sequences using partial order multiple sequence alignment graphs. Pac Symp Biocomp. 2004; 9:29–41.
- Polakoski KL, Parrish RF. Boar proacrosin. Purification and preliminary activation studies of proacrosin isolated from ejaculated boar sperm. J Biol Chem. 1977; 252:1888–94.
- Parrish RF, Polakoski KL. An apparent high molecular weight form of boar proacrosin resulting from the presence of a protein that binds to proacrosin. Anal Biochem. 1978; 87:108–13.
- Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, et al. Announcing cIMPACT-NOW: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica. 2017; 133:1–3.
- Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017; 31:737–54.e6. doi: 10.1016/j.ccell.2017.05.005